Concomitant LATE-NC in Alzheimer's disease is not associated with increased tau or amyloid-β pathological burden

被引:16
|
作者
McAleese, K. E. [1 ]
Walker, L. [1 ]
Erskine, D. [1 ]
Johnson, M. [1 ]
Koss, D. [1 ]
Thomas, A. J. [1 ]
Attems, J. [1 ]
机构
[1] Newcastle Univ, Translat & Clin Res Inst, Campus Ageing & Vital, Newcastle Upon Tyne NE4 5PL, Tyne & Wear, England
基金
英国医学研究理事会;
关键词
Alzheimer's disease; LATE-NC; TDP-43; tau pathology; FRONTOTEMPORAL LOBAR DEGENERATION; BINDING PROTEIN 43; HIPPOCAMPAL SCLEROSIS; NEUROPATHOLOGIC ASSESSMENT; TDP-43; PATHOLOGY; COGNITIVE IMPAIRMENT; NATIONAL INSTITUTE; DEMENTIA; GUIDELINES; OLD;
D O I
10.1111/nan.12664
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Aims Limbic-predominant age-related TDP-43 encephalopathy neuropathological change (LATE-NC) is present in approximately 50% of Alzheimer's disease (AD) cases and is associated with accelerated cognitive decline. Studies indicate a potential synergistic relationship between LATE-NC and hyperphosphorylated tau. It is unknown if LATE-NC is an independent driver of cognitive impairment or exerts its influence through synergistic relationships with tau. This cliniconeuropathological study investigated the impact of LATE-NC on quantified measures of AD-associated pathology and its impact on clinical measures. Methods A total of 61 AD cases underwent neuropathological assessment for LATE-NC and quantitative assessment [area covered by immunoreactivity (IR)] for early conformational tau (MC-1), late-stage hyperphosphorylated tau (AT8) and amyloid-beta in the amygdala and five neocortical regions. Clinical measures included age of disease onset, final Mini-Mental State Examination (MMSE) score and rate of cognitive decline. Results LATE-NC was present in 41 AD cases (AD/LATE-NC; 67.2%). No significant differences in MC-1-IR, AT8-IR or 4G8-IR were observed in any region between AD/LATE-NC and AD without LATE-NC, indicating no accelerated aggregation or hyperphosphorylation of tau proteins in the AD/LATE-NC cases. Final MMSE was significantly lower in AD/LATE-NC cases and was significantly associated with LATE-NC score even when controlled for the presence of both MC-1-IR and AT8-IR (P = 0.009). Conclusion The presence of LATE-NC in AD is not associated with an increase in the burden of early or late tau or A beta pathology. LATE-NC is associated with a lower final MMSE score independent of tau pathology.
引用
收藏
页码:722 / 734
页数:13
相关论文
共 50 条
  • [31] New therapeutics beyond amyloid-β and tau for the treatment of Alzheimer’s disease
    Feng Zhang
    Ru-jia Zhong
    Cheng Cheng
    Song Li
    Wei-dong Le
    Acta Pharmacologica Sinica, 2021, 42 : 1382 - 1389
  • [32] Temporal trajectories of in vivo tau and amyloid-β accumulation in Alzheimer’s disease
    Min Seok Baek
    Hanna Cho
    Hye Sun Lee
    Jae Yong Choi
    Jae Hoon Lee
    Young Hoon Ryu
    Myung Sik Lee
    Chul Hyoung Lyoo
    European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47 : 2879 - 2886
  • [33] Temporal trajectories of in vivo tau and amyloid-β accumulation in Alzheimer's disease
    Baek, Min Seok
    Cho, Hanna
    Lee, Hye Sun
    Choi, Jae Yong
    Lee, Jae Hoon
    Ryu, Young Hoon
    Lee, Myung Sik
    Lyoo, Chul Hyoung
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2020, 47 (12) : 2879 - 2886
  • [34] Astrocyte biomarker signatures of amyloid-β and tau pathologies in Alzheimer’s disease
    João Pedro Ferrari-Souza
    Pâmela C. L. Ferreira
    Bruna Bellaver
    Cécile Tissot
    Yi-Ting Wang
    Douglas T. Leffa
    Wagner S. Brum
    Andréa L. Benedet
    Nicholas J. Ashton
    Marco Antônio De Bastiani
    Andréia Rocha
    Joseph Therriault
    Firoza Z. Lussier
    Mira Chamoun
    Stijn Servaes
    Gleb Bezgin
    Min Su Kang
    Jenna Stevenson
    Nesrine Rahmouni
    Vanessa Pallen
    Nina Margherita Poltronetti
    William E. Klunk
    Dana L. Tudorascu
    Ann D. Cohen
    Victor L. Villemagne
    Serge Gauthier
    Kaj Blennow
    Henrik Zetterberg
    Diogo O. Souza
    Thomas K. Karikari
    Eduardo R. Zimmer
    Pedro Rosa-Neto
    Tharick A. Pascoal
    Molecular Psychiatry, 2022, 27 : 4781 - 4789
  • [35] Application of Yeast to Study the Tau and Amyloid-β Abnormalities of Alzheimer's Disease
    Porzoor, Afsaneh
    Macreadie, Ian G.
    JOURNAL OF ALZHEIMERS DISEASE, 2013, 35 (02) : 217 - 225
  • [36] Comparison of Tau and Amyloid-β Targeted Immunotherapy Nanoparticles for Alzheimer's Disease
    Mashal, Yara
    Abdelhady, Hosam
    Iyer, Arun K.
    BIOMOLECULES, 2022, 12 (07)
  • [37] Amyloid-β Increases Tau by Mediating Sirtuin 3 in Alzheimer’s Disease
    Junxiang Yin
    Pengcheng Han
    Melissa Song
    Megan Nielsen
    Thomas G. Beach
    Geidy E. Serrano
    Winnie S. Liang
    Richard J. Caselli
    Jiong Shi
    Molecular Neurobiology, 2018, 55 : 8592 - 8601
  • [38] Amyloid-β and tau - a toxic pas de deux in Alzheimer's disease
    Ittner, Lars M.
    Goetz, Juergen
    NATURE REVIEWS NEUROSCIENCE, 2011, 12 (02) : 67 - 72
  • [39] Pyroglutamylated amyloid-β correlates with hyperphosphorylated tau and severity of Alzheimer's disease
    Walker, L.
    Mandler, M.
    Santic, R.
    Hanson, P.
    Upadhaya, A. R.
    Colloby, S. J.
    Morris, C. M.
    Thal, D. R.
    Thomas, A. J.
    Schneeberger, A.
    Attems, J.
    BRAIN PATHOLOGY, 2014, 24 : 42 - 42
  • [40] Amyloid-β and tau — a toxic pas de deux in Alzheimer's disease
    Lars M. Ittner
    Jürgen Götz
    Nature Reviews Neuroscience, 2011, 12 : 67 - 72